Pfizer (NYSE: PFE), now famous as the co-developer of the coronavirus vaccine BNT162b2, released its final quarterly results for fiscal 2020 on Tuesday.
These show that the company earned $11.68 billion in revenue, which was 12% higher than the same quarter of 2019. Of that, BNT162b2 — which received emergency use authorization from the FDA in December — was responsible for $154 million.
On the bottom line, Pfizer grew its non-GAAP (adjusted) net profit by 15% to nearly $2.37 billion, or $0.42 per share.
